Eli Lilly & Co. vs Protagonist Therapeutics, Inc
LLY vs PTGX — side-by-side comparison from reported financials. LLY leads 8, PTGX leads 2 of 10 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
| Metric | LLY | PTGX |
|---|---|---|
| Price | $1 177.20 | $143.00 |
| Market cap | $1.05T | $9.25B |
| Revenue (TTM) | $79.7B | $275M |
| Revenue growth | +31.7% | +20.1% |
| Net margin | 33.5% | 30.2% |
| Free cash flow | $18.2B | $131M |
| Net cash (debt) | ($35.2B) | — |
| 1-year price return | +37.6% | +113.3% |
| P/E | 41.6 | 112.2 |
| P/E vs own history (cheap-side %) | 88% | 21% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 12% |
| Altman Z-score | 7.10 | 139.54 |
| CV checks passed | 11 of 11 | 6 of 11 |
| Employees | 50,000 | 141 |
Full résumé-style profiles: LLY CV · PTGX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.